KURA logo

KURAKura Oncology Inc

$8.74
$0.03
(0.34%)
Today
Closed $8.74
$0.56
(6.41%)
After Hours
Updated: 07:58 PM EDT
Reported EarningsMay 12
Mkt Cap$775.89M
Vol3.23M
News
all
press releases
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of +5.33% and +21.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
More News
News Placeholder
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Kura Oncology (KURA) Projected to Post Quarterly Earnings on Thursday
Kura Oncology (NASDAQ:KURA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-kura-oncology-inc-stock...
MarketBeat
News Placeholder
Moody Aldrich Partners LLC Buys New Position in Kura Oncology, Inc. $KURA
Moody Aldrich Partners LLC bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 179,728 shares of the company's s...
MarketBeat
News Placeholder
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data
Kura Oncology shares jump 8% as FIT-001 data show strong tumor response and disease control with darlifarnib combination in pretreated renal cancer patients.
Zacks
News Placeholder
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?
Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages
Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has received an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the stock, MarketBeat reports...
MarketBeat
News Placeholder
Kura Oncology (NASDAQ:KURA) Stock Price Up 9.7% - Time to Buy?
Kura Oncology (NASDAQ:KURA) Trading Up 9.7% - Here's What Happened...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.